Indian Generics Face Lower Third-Quarter Income Without New Launches
This article was originally published in PharmAsia News
Increasing competition and pressures in the United States and Europe to hold down the price of generic drugs threaten to reduce the income reports of Indian pharmaceuticals for the third quarter of 2007. The reduction also is expected in part because of lower income for authorized generics and the effects of a strong rupee. A Sarabjit Kour Nangra research vice president noted no new products were launched in India during the third quarter. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.